Chen, L., Ye, Z., Liu, G., Chi, Y., Wang, J., Wei, S., et al. (2022) 85P Tislelizumab Combined with Apatinib and Oxaliplatin plus S1 as Neoadjuvant Therapy for Borrmann IV Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: A Single-Arm Multicenter Trial (TAOS-3B-Trial). Immuno-Oncology and Technology, 16, e100189.
https://doi.org/10.1016/j.iotech.2022.100189

has been cited by the following article:

• TITLE: Current Status and Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer

  AUTHORS: Junjian Liu, Tian Wei, Zhiping Xiang, Yinlu Ding

  KEYWORDS: Locally Advanced Gastric Cancer, Adjuvant Chemotherapy, Neoadjuvant Chemotherapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.3, March 30, 2023

  ABSTRACT: Gastric cancer is one of the most common malignant tumours worldwide, with a high degree of malignancy and a poor prognosis. While early gastric cancer can be cured by surgical treatment, locally advanced gastric cancer requires neoadjuvant therapy to shrink the tumour, suppress potential metastases, achieve down-staging, and provide patients with the opportunity for radical surgery to prolong their survival. This article reviews the current status and progress of neoadjuvant chemotherapy for locally advanced gastric cancer.